Tags

Type your tag names separated by a space and hit enter

NCCN Guidelines Updates: Management of Prostate Cancer.
J Natl Compr Canc Netw 2019; 17(5.5):583-586JN

Abstract

Updates to the NCCN Guidelines for Prostate Cancer include further refinements in taking a family history, new recommendations for germline and somatic testing, use of androgen receptor blockers for nonmetastatic castration-resistant prostate cancer, advice regarding intermittent versus continuous androgen deprivation therapy, and consideration of whether to treat the primary tumor in men diagnosed with de novo metastatic prostate cancer.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31117038

Citation

Mohler, James L., and Emmanuel S. Antonarakis. "NCCN Guidelines Updates: Management of Prostate Cancer." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 17, no. 5.5, 2019, pp. 583-586.
Mohler JL, Antonarakis ES. NCCN Guidelines Updates: Management of Prostate Cancer. J Natl Compr Canc Netw. 2019;17(5.5):583-586.
Mohler, J. L., & Antonarakis, E. S. (2019). NCCN Guidelines Updates: Management of Prostate Cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 17(5.5), pp. 583-586. doi:10.6004/jnccn.2019.5011.
Mohler JL, Antonarakis ES. NCCN Guidelines Updates: Management of Prostate Cancer. J Natl Compr Canc Netw. 2019 May 1;17(5.5):583-586. PubMed PMID: 31117038.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - NCCN Guidelines Updates: Management of Prostate Cancer. AU - Mohler,James L, AU - Antonarakis,Emmanuel S, PY - 2019/5/23/entrez PY - 2019/5/23/pubmed PY - 2019/5/23/medline SP - 583 EP - 586 JF - Journal of the National Comprehensive Cancer Network : JNCCN JO - J Natl Compr Canc Netw VL - 17 IS - 5.5 N2 - Updates to the NCCN Guidelines for Prostate Cancer include further refinements in taking a family history, new recommendations for germline and somatic testing, use of androgen receptor blockers for nonmetastatic castration-resistant prostate cancer, advice regarding intermittent versus continuous androgen deprivation therapy, and consideration of whether to treat the primary tumor in men diagnosed with de novo metastatic prostate cancer. SN - 1540-1413 UR - https://www.unboundmedicine.com/medline/citation/31117038/NCCN_Guidelines_Updates:_Management_of_Prostate_Cancer L2 - https://jnccn.org/doi/10.6004/jnccn.2019.5011 DB - PRIME DP - Unbound Medicine ER -